Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ending of its deal with Hims & Hers jeopardizes the healthcare platform's goal to lead the weight loss market.

As such, Novo Nordisk ended its collaboration with Hims & Hers over concerns of illegal mass compounding and deceptive marketing. 1 In a statement, Novo states that it conducted an investigation into the production of mass compounded semaglutides and found that many of the drugs offered by telehealth services are manufactured by suppliers in China.